BioCentury
ARTICLE | Financial News

Adlai Nortye raises $50M in series B

June 26, 2018 8:49 PM UTC

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also participated.

Adlai Nortye has in-licensed two cancer immunotherapy candidates, including Reolysin pelareorep and E7046 (AN0025)...